Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07152600
PHASE3

Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults

Sponsor: Qingyuan Zhan

View on ClinicalTrials.gov

Summary

Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults. It predominantly affects young individuals, progresses rapidly, and is associated with a high incidence of respiratory failure and multiple organ dysfunction. At present, there is no effective antiviral therapy available in China, and the reported mortality rate ranges from 41.5% to 80%. How to effectively reduce the mortality of severe adenovirus pneumonia, on the basis of conventional supportive care, is crucial for improving the prognosis of critically ill patients and alleviating the burden on families and society. We are currently conducting an adaptive, randomized, open-label controlled trial aimed at reducing mortality in severe adenovirus pneumonia. The primary objective of this study is to evaluate the efficacy and safety of adjunctive corticosteroid therapy at different dosages, in addition to early standard supportive treatment, in lowering mortality among patients with severe adenovirus pneumonia.

Official title: An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Adenovirus Community-Acquired Pneumonia in Adults

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

262

Start Date

2026-02-01

Completion Date

2027-12-31

Last Updated

2026-01-21

Healthy Volunteers

No

Interventions

DRUG

Saline (0.9%, sterile, for infusion)

Sailine as control

DRUG

low dose Methylprednisolone

Methylprednisolone 0.5mg/kg ivgtt qd

DRUG

Moderate dose Methylprednisolone

Methylprednisolone 1.0mg/kg ivgtt qd